A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression

Journal of Clinical Psychiatry

Volumn 67, Issue 5, 2006, Pages 798-806

  Corya, Sara A ^a   Perlis, Roy H ^b   Keck Jr , Paul E ^c   Lin, Daniel Y ^a   Case, Michael G ^a   Williamson, Doug J ^a   Tohen, Mauricio F ^b  

^a ELI LILLY AND COMPANY   (United States)

^b MCLEAN HOSPITAL   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE MESILATE; BENZODIAZEPINE; BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUOXETINE PLUS OLANZAPINE; LORAZEPAM; OLANZAPINE; PLACEBO; TRIHEXYPHENIDYL;

ADULT; AGED; ANXIETY; ARTICLE; ASTHENIA; BACKACHE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INCIDENCE; INCREASED APPETITE; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MANIA; METHODOLOGY; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NERVOUSNESS; PRIORITY JOURNAL; RATING SCALE; RECURRENT DISEASE; REMISSION; RETROSPECTIVE STUDY; RHINITIS; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; URINARY TRACT INFECTION; WEIGHT GAIN;

EID: 33745330396     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0514     Document Type: Article

References (30)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
2. Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system: epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993;50:85-94
3. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-537
4. Keller MB, Lavori PW, Coryell W, et al. Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness. JAMA 1986;255:3138-3142
5. Altshuler LL, Gitlin MJ, Mintz J, et al. Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. J Clin Psychiatry 2002;63:807-811
6. Gitlin MJ, Swendsen J, Heller TL, et al. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995;152:1635-1640
7. Dilsaver SC, Chen YW, Swann AC, et al. Suicidality, panic disorder and psychosis in bipolar depression, depressive-mania and pure-mania. Psychiatry Res 1997:73:47-56
8. Bowden CL, Krishnan AA. Pharmacotherapy for bipolar depression: an economic assessment. Expert Opin Pharmacother 2004;5:1101-1107
9. Bryant-Comstock L, Stender M, Devercelli G. Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disord 2002;4:398-405
10. Gyulai L, Bowden CL, McElroy SL, et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003;28:1374-1382
11. Ghaemi SN, Lenox MS, Baldessarini RJ. Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J Clin Psychiatry 2001;62:565-569
12. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. BrJ Psychiatry 1994;164:549-550
13. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group [Erratum in Arch Gen Psychiatry 2002;59:91]. Arch Gen Psychiatry 2000;57:841-849
14. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-1088
15. First MB, Gibbon M, Spitzer RL, et al. Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Patient Version. Washington, DC: American Psychiatric Press; 1997
16. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
17. Spearing MK, Post PM, Leverich GS, et al. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997;73:159-171
18. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 1978;133:429-435
19. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19
20. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Bethesda, Md: National Institute of Mental Health; 1976
21. COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. 3rd ed. Rockville, Md: Division of Drug and Biological Product Experience, Center for Drug and Biologics, Food and Drug Administration, Department of Health and Human Services; 1989
22. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64: 1013-1024
23. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004;65:432-441
24. Post RM, Leverich GS, Nolen WA, et al. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network. Bipolar Disord 2003;5:396-406
25. Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004;161:1537-1547
26. Altshuler L, Suppes T, Black D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003;160:1252-1262
27. Post RM, Altshuler LL, Leverich GS, et al. Switch rate on venlafaxine compared with bupropion and sertraline [abstract]. Acta Psychiatr Scand 2004;110:32
28. Vieta E, Martinez-Aran A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002;63: 508-512
29. Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v mood stabiliser alone. Br J Psychiatry 2004;184:337-345
30. Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005;162: 1281-1290